Baudax Bio announces the cancellation of the postponed portion
MALVERN, Pa., May 28, 2021 (GLOBE NEWSWIRE) – Baudax Bio, Inc. (NASDAQ: BXRX) (the “Company”), A pharmaceutical company specializing in the development and commercialization of innovative products for acute care facilities, today announced that it has decided to withdraw from shareholder review of Proposal 3 set out in its definitive proxy statement filed with the Securities and Exchange Commission on March 11, 2021, relating to an increase in the number of common shares authorized for issuance under the Company’s amended and restated certificate of incorporation. As a result, the company has decided to cancel the resumed annual meeting of shareholders for consideration of Proposal 3, which had previously been adjourned only in relation to Proposal 3 at 10:00 a.m. Eastern Time. , June 3, 2021. All others The elements set out in the company’s definitive proxy statement were submitted to the shareholders ‘vote at the company’s annual shareholders’ meeting on April 7, 2021.
About Baudax Bio
Baudax Bio is a pharmaceutical company specializing in the development and marketing of innovative products for acute care facilities. The launch of Baudax Bio’s first commercial product, ANJESO®, began in mid-2020. ANJESO is the first and only 24-hour preferred intravenous (IV) COX-2 nonsteroidal anti-inflammatory drug (NSAID) for the management of moderate to severe pain, which can be administered alone or in combination with other non-NSAID pain relievers. He has completed three phase III clinical trials, including two pivotal efficacy trials, a large double-blind phase III safety trial, and a phase IIIb program evaluating ANJESO and its economic impact on health in settings specific surgical procedures. In addition to ANJESO, Baudax Bio has a portfolio of other innovative pharmaceutical active ingredients, in particular two new neuromuscular blocking agents (NMBA) and a proprietary chemical reversal agent specific to these NMBAs which is currently the subject of ‘preclinical studies. For more information, please visit www.baudaxbio.com.
This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements reflect Baudax Bio’s expectations with respect to its future performance and opportunities, which involve substantial risks and uncertainties. When used herein, the words “anticipate”, “believe”, “estimate”, “may”, “to come”, “plan”, “target”, “objective”, “intend” and ” expect ”and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio on the date of publication on this website and are subject to a number of risks, uncertainties and other factors that could cause the performance of Baudax Bio differ materially from those expressed in, or implied by, these forward-looking statements. Baudax Bio assumes no obligation to update these forward-looking statements. These forward-looking statements should be considered in conjunction with the risks and uncertainties that may affect our business and future results included in our documents filed with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements must be considered in conjunction with the risks and uncertainties likely to affect Baudax Bio’s activities and future results included in the documents filed by Baudax Bio with the Securities and Exchange Commission at the following address: www.sec.gov.
Investor Relations Contact:
Partners Argot Sam Martin / Claudia Styslinger